Pharmaceutical Executive announced the top 50 biopharma companies in the world in 2021. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) ranked the 38th out of the top 50. 2021 is the third consecutive year Hengrui Pharma was listed in the ranking.

From 2019 to 2021, the ranking of Hengrui Pharma has risen from No.47 to No. 38, with an increase in revenue from 2.57 billion USD to 4.20 billion USD.

The top 50 list of PharmExec has been announced by Pharmaceutical Executive annually since 2000, with a history of 22 years. This year's ranking was mainly based on the revenue of prescription drugs in the fiscal year of 2020.

As a pioneer and leader of China's innovative drug developer, Hengrui Pharma has been dedicated to innovation. Our cost of research and development is increasing year by year. We spent 768 million USD (4.99 billion RMB) in R&D in 2020, which is nearly 18% of the 2020 revenue. In 2021 Q1, we continued our commitment to innovation with an expense of 203 million USD in R&D, representing an increase of 62.26% compared with the R&D expense in 2020 Q1.

In the past few years, Hengrui Pharma has obtained outstanding achievements under the innovation and globalization-driven strategy. As more and more innovative drugs developed by Hengrui Pharma enter the market, the R&D capability of Chinese pharmaceutical companies has drawn the attention of the global biopharma industry.